Biosimilar Antibodies

Panitumumab is a fully human monoclonal antibody of the IgG2 subclass, designed to specifically target the epidermal growth factor receptor (EGFR). It exhibits potent anti-tumor properties by inhibiting tumor cell proliferation, survival, and angiogenesis. This monoclonal antibody is particularly useful in cancer research, including studies focused on colon cancer, providing a critical tool for understanding the role of EGFR in cancer pathology and therapy.

Nofazinlimab (CS1003) is a humanized IgG4 monoclonal antibody targeting PD-1. This antibody is specifically designed for use in research involving unresectable hepatocellular carcinoma (uHCC), offering a promising tool for investigating the modulation of immune checkpoint pathways in cancer immunotherapy.

Golocdacimab (MEDI6570) is a fully human monoclonal antibody that targets the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). This antibody is specifically designed for the investigation of its therapeutic potential in type 2 diabetes. Golocdacimab's specificity for LOX-1 makes it a valuable tool for research focused on understanding the role of this receptor in metabolic diseases.

Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.

The Anti-SERPINE1 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the SERPINE1 protein. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, exhibiting a predicted molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is essential for researchers focusing on the biological roles and regulatory mechanisms involving SERPINE1 in various pathological and physiological processes.

Mavrilimumab (CAM 3001) is a monoclonal antibody designed to target and bind specifically to the α subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. By attaching to this subunit, Mavrilimumab effectively inhibits the downstream intracellular signaling pathways activated by GM-CSF. This interaction is crucial, as GM-CSF is implicated as a potential mediator in the exacerbation of inflammatory responses that can lead to respiratory failure and mortality. This antibody is particularly relevant in research focused on inflammatory diseases and immune response regulation.

Givastomig is a monoclonal antibody designed to target and inhibit the activity of TNFRSF9/CLDN18. This biologic is engineered for specificity against TNFRSF9/CLDN18, making it suitable for research applications focused on understanding the role of this receptor in disease processes and therapeutic interventions.

Gimistotug is a humanized IgG1κ monoclonal antibody specifically targeting TNFRSF4. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody that targets R-spondin 3 (RSPO3). It is designed for use in scientific studies investigating advanced, relapsed, and refractory solid tumors. This antibody may serve as a valuable tool in oncology research, particularly in exploring the role of RSPO3 in tumor progression and therapy resistance.

Nivatrotamab (Hu3F8-BsAb) is a humanized bispecific antibody targeting both GD2 and CD3 antigens. This dual specificity enables Nivatrotamab to function as a T-cell engager, facilitating the direct interaction between T-cells and GD2-expressing tumor cells. It is primarily utilized in research focused on neuroblastoma, a cancer that commonly arises from neural crest cells in the adrenal glands and can also develop in nerve tissues throughout the body. Nivatrotamab's mechanism of action and its role in recruiting and activating T-cells against GD2-positive cancer cells make it a valuable tool in immuno-oncology research.

Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody designed to specifically bind to a central tau epitope, encompassing amino acids 235-250. This antibody is particularly useful in the study of Alzheimer’s disease (AD), offering potential insights into disease mechanisms and pathways influenced by tau protein aggregation. Bepranemab's targeted binding affinity makes it a valuable tool for researchers focusing on the pathological features of AD and related tauopathies.

Caxmotabart is a humanized IgG1κ monoclonal antibody designed to specifically target ERBB2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Nolavetbart is a human IgG2 κ monoclonal antibody targeting the IL31RA receptor in the Canlupfam species. For accurate experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

IMC-2C5 is a fully human monoclonal antibody that acts as an antagonist to platelet-derived growth factor receptor beta (PDGFRβ). This antibody is designed to enhance antitumor activity and potentiate the effects of antiangiogenic agents across a diverse array of human cancers. Targeting PDGFRβ, IMC-2C5 has demonstrated efficacy in inhibiting tumor growth and angiogenesis, making it a valuable tool for cancer research and therapeutic development.

Sovipostobart is a human monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CTLA-4 with a cleavable prodomain. It functions as both an immunostimulant and an antineoplastic agent. This biologic is designed to modulate the immune system by inhibiting CTLA-4, a protein that downregulates immune responses, thereby enhancing the body's antitumor activity. Sovipostobart is applicable in the study of immune checkpoint blockade therapies and is relevant for research focused on cancer immunotherapy.

Suvizumab (KD-247) is a neutralizing monoclonal antibody targeting HIV-1. Demonstrating potent efficacy, Suvizumab effectively neutralizes diverse HIV-1 strains including HIV-1MN, HIV-1SF2, and HIV-189.6, with respective IC50 values of 0.1 µg/mL, 1.0 µg/mL, and 0.2 µg/mL. This antibody has been shown to significantly reduce viral load, offering a promising therapeutic option for the management of HIV infection. Suvizumab is well-tolerated and holds potential for both therapeutic and prophylactic applications in HIV management.

KRN-330 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target GPA33, a cell surface antigen predominantly expressed in colorectal cancer cells. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control, is recommended.

Tomuzotuximab is a fully human, glycoengineered IgG1 monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR). This recombinant antibody is engineered to bind selectively to EGFR, a receptor critically involved in the proliferation and survival of various cancer cells. By inhibiting EGFR signaling, Tomuzotuximab exhibits potent anticancer activities, making it a valuable tool for research in oncology and therapeutic development.

Semorinemab (RG 6100) is a humanized IgG4 monoclonal antibody designed to specifically target the N-terminal region of the Tau protein, encompassing amino acid residues 6-23. This antibody exhibits a high affinity for human Tau, with a dissociation constant (Kd) of 3.8 nM, indicating robust binding efficiency. Semorinemab is primarily utilized in the investigation of Alzheimer's Disease, serving as a critical tool in research focused on the pathophysiology and potential therapeutic interventions for tauopathies.

Lerdelimumab (CAT-152) is a recombinant human monoclonal antibody of the IgG4 subclass that specifically targets transforming growth factor-beta 2 (TGF-β2). This antibody is utilized in research as an anti-scarring agent, particularly in studies related to glaucoma. Its mechanism of action involves neutralizing the biological activity of TGF-β2, a cytokine implicated in the pathogenesis of fibrosis and scarring.

Sapelizumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target IL-6Ra/CD126. This antibody comprises a human IgG2 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 145 kDa. For experimental controls, the appropriate isotype control is Human IgG2 kappa. Sapelizumab is utilized primarily in research focused on the modulation and study of immune response pathways influenced by IL-6Ra.

Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) specifically designed to target a unique epitope of CD2 subset 1, a cell-surface glycoprotein prevalently expressed on multiple myeloma cells. This targeted approach allows for the direct delivery of cytotoxic agents to the cancer cells, potentially enhancing therapeutic efficacy while minimizing off-target effects. Azintuxizumab vedotin is primarily utilized in research focused on the treatment and understanding of multiple myeloma.

The Anti-EPOR Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the Erythropoietin Receptor (EPOR). This antibody has a predicted molecular weight of 150 kDa. For isotype control, the Human IgG2 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological pathways and therapeutic targets involving erythropoietin and its receptor.

Daretabart is a humanized IgG1 kappa monoclonal antibody specifically targeting GD2, a disialoganglioside prevalent on tumor cells. This antibody is designed for use in anti-tumor research to elucidate the role of GD2 in cancer progression and potential therapeutic interventions. The appropriate isotype control for Daretabart is Human IgG1 kappa Isotype Control, which is essential for validating the specificity and ensuring the accuracy of experimental results involving this antibody.

Gremubamab (MEDI3902) is a humanized IgG1 kappa monoclonal antibody designed to target both the PcrV protein and Psl exopolysaccharide on Pseudomonas aeruginosa. By binding to these specific antigens, Gremubamab offers a dual-action approach in the study of Pseudomonas aeruginosa infections, making it a valuable tool for research in microbial pathogenesis and immune response mechanisms.

Anti-PVRIG (GSK4381562) is a human monoclonal antibody of the immunoglobulin G1 (IgG1) class, targeting the poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG, also known as CD112R). This antibody is designed to modulate immune response through its inhibitory effects on the PVRIG pathway, which is implicated in immune checkpoint regulation. The interaction between Anti-PVRIG and its target has the potential to enhance antitumor immune activity by alleviating immune suppression in the tumor microenvironment, thereby offering therapeutic benefits in oncology research and treatment.

Mevonlerbart is an IgG4κ monoclonal antibody specifically designed to target Human Felcat allergen 1, a known allergenic protein. This antibody is optimized for high specificity and affinity, making it an ideal tool for research into allergic responses and potential therapeutic interventions related to Felcat allergen 1.

Silevimig is a monoclonal antibody specifically targeting the rabies virus (RABV). This antibody binds to the viral surface proteins, neutralizing the virus and preventing its propagation. Silevimig is utilized extensively in research focusing on the development of rabies treatments and vaccines, and in studies exploring the pathophysiology of this virus.

SIM-0235 is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target and inhibit TNFR2 (Tumor Necrosis Factor Receptor 2). For experimental consistency and control, it is recommended to use Human IgG1 kappa as an isotype control. This product is pivotal for research focused on the modulation of immune responses and inflammation, particularly in studies related to cancer and autoimmune diseases.

CDP-484 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-1 beta (IL-1β). This antibody is constructed from a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 145.74 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. CDP-484's specificity and affinity for IL-1β make it an essential tool for research focused on inflammation, immune response, and related pathological conditions.

Amubarvimab (BRII-196) is a human IgG1 monoclonal antibody designed to target distinct, non-competing epitopes on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It exhibits a binding affinity with a dissociation constant (K_D) of 5.88 nM, demonstrating potent neutralization capabilities against various SARS-CoV-2 variants. This specificity and efficacy make Amubarvimab a valuable tool for research into the mechanisms of viral entry and immune evasion.

Natalizumab is a recombinant, humanized IgG4 monoclonal antibody that targets α4β1-integrin, effectively inhibiting its interaction with vascular cell adhesion molecule-1 (VCAM-1). This antibody is utilized in the management of relapsing-remitting multiple sclerosis and Crohn's disease. It represents the inaugural targeted therapeutic approach that impedes lymphocyte migration into the central nervous system (CNS), thereby preventing acute demyelinating episodes.

Vopratelimab (JTX-2011) is a humanized IgG1-kappa agonist monoclonal antibody designed to selectively target the Inducible T-cell CO-Stimulator (ICOS), a critical molecule in the modulation of T-cell activity. This antibody exhibits strong species cross-reactivity, demonstrating binding affinities of 0.93 nM for human ICOS, 0.46 nM for cynomolgus ICOS, 3.7 nM for rat ICOS, and 0.64 nM for murine ICOS. Vopratelimab is primarily utilized in research focused on enhancing antitumor immune responses, making it a valuable tool in oncology and immunotherapy studies.

Vibecotamab (XmAb14045) is a bispecific antibody designed to target CD123 and CD3, facilitating the selective engagement of T cells and the subsequent targeted elimination of cells expressing CD123. This antibody demonstrates potent antitumor activity, making it particularly valuable for research in acute myeloid leukemia (AML). Vibecotamab's mechanism of action and specificity for CD123-expressing cells underscore its utility in studies aimed at investigating immune-mediated approaches to cancer therapy.

Budoprutug is a human IgG1 κ monoclonal antibody targeting CD19. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

AMG-108 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-1R1/CD121a. This antibody consists of a human IgG2 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For experimental controls, the Human IgG2 kappa, Isotype Control is recommended.

The Anti-RSPO1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target R-spondin 1 (RSPO1). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Emirodatamab is a monoclonal antibody designed to target both CD3E and FLT3. This dual-specificity allows for potential applications in modulating immune responses and targeting FLT3-associated malignancies. Emirodatamab's unique ability to bind these two distinct antigens makes it a valuable tool for research in immunotherapy and hematologic cancers.

Mazorelvimab (CTB012) is a humanized IgG1κ monoclonal antibody designed to target the rabies virus (RABV) by binding to non-overlapping epitopes on the RABV glycoprotein. This antibody specifically interacts with highly discontinuous, conserved residues that are distinct from antigenic site III, ensuring unique specificity. Mazorelvimab is primarily investigated for its potential use in the prevention of rabies, offering a promising therapeutic approach in rabies prophylaxis.

The Anti-CD8α Antibody (OKT-8) is a chimeric mouse IgG2a monoclonal antibody that specifically targets human CD8α. It is recommended to use Mouse IgG2a kappa as an isotype control for this antibody to ensure specificity and accurate interpretation of results in experimental setups.

Tavolixizumab, also known as MEDI 0562 or Tavolimab, is a human monoclonal antibody that targets TNFRSF4 (TNF receptor superfamily member 4). This antibody is specifically designed for research applications in cancer immunology, focusing on the modulation of immune responses in oncological studies. Tavolixizumab binds selectively to TNFRSF4, a receptor implicated in the co-stimulation of T cells, playing a crucial role in immune regulation and potential anti-tumor activity. This product is ideal for researchers studying the mechanisms of immune activation and its effects on cancer progression.

The Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Adenosine A2a Receptor (AA2AR), a critical component involved in various physiological processes including cardiovascular function and immune response. This antibody is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and has a predicted molecular weight of 146.66 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for researchers focusing on signal transduction pathways influenced by adenosine receptors and is suitable for a range of immunological applications.

STX-100 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Integrin αVβ6 (ITGAV & ITGB6). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.12 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody designed to target and neutralize immunoglobulin E (IgE). This antibody is specifically engineered for the treatment and study of allergic reactions and other conditions mediated by excessive or inappropriate IgE responses.

Bermekimab (MABp1) is a human monoclonal antibody designed to specifically target and neutralize interleukin-1 alpha (IL-1α). By inhibiting this cytokine, Bermekimab effectively reduces tumor-associated inflammation, offering potential therapeutic benefits in the management of cancer-related inflammatory processes.

Bermekimab (MABp1) is a human monoclonal antibody designed to specifically target and neutralize interleukin-1 alpha (IL-1α). By inhibiting this cytokine, Bermekimab effectively reduces tumor-associated inflammation, offering potential therapeutic benefits in the management of cancer-related inflammatory processes.

Oberotatug is a human monoclonal antibody of the IgG1κ subclass that specifically targets the lymphocyte antigen LY75. This antibody is designed for high specificity and affinity in binding to LY75, a receptor involved in antigen processing and presentation. Oberotatug is utilized primarily in research focused on immune response modulation and the study of lymphocyte signaling pathways.